Saul Ewing to Defend Samsung Bioepis in High-Stakes Amgen Patent Infringement Case

Saul Ewing’s legal team has been tapped to represent Samsung Bioepis in a recent patent infringement lawsuit filed by California pharmaceutical giant Amgen. The dispute centers on bone-treatment drugs that Samsung Bioepis is developing, which Amgen argues would directly compete with two of its leading products. This case marks a significant point of contention in the biotechnology industry, where patent law plays a critical role in shaping market dynamics and innovation pathways. For more details on the unfolding legal battle, visit the [source article](https://www.feedblitz.com/fake/) for comprehensive coverage.